Article Figures & Data
Figures
- Figure 1
PSA kinetics before and after fractionated pRT that was delivered during systemic treatment with docetaxel chemotherapy (A and B) and abiraterone (C). PSA, prostate specific antigen; pRT, palliative radiotherapy.
- Figure 2
Bone scan appearances (case 1) during the treatment course demonstrate response to systemic chemotherapy after pRT for metastatic bone disease. (A) Bone scan prior to starting chemotherapy (PSA =106 ng/mL); (B) Bone scan after four cycles of chemotherapy showed no change, but patient developed increasing bone pain with rapid biochemical progression (PSA =220 ng/mL); (C) Bone scan performed after pRT, and further six cycles of chemotherapy showed a significant reduction in uptake (PSA =30 ng/mL). pRT, palliative radiotherapy; PSA, prostate specific antigen.
Tables
- Table 1
Patient and disease-related characteristics combined with initial management and subsequent lines of therapy
Item Case 1 Case 2 Case 3 Diagnosis and management (first-line therapy) • 64 years • 72 years • 78 years • August 2010 • March 2008 • November 2010 • PSA =450 ng/mL • PSA =1,170 ng/mL • PSA =1,400 ng/mL • Skeletal metastasis • Skeletal metastasis • Skeletal metastasis • Bicalutamide monotherapy • LHRH analogue therapy • LHRH analogue + bicalutamide (MAB) • Zoledronic acid infusions • PSA nadir 4.3 in September 2009 • PSA nadir 36.5 in November 2011 • PSA nadir in November 2010 • Palliative radiotherapy (spine) Second-line therapy • November 2011 • March 2010 • May 2012 • PSA =23 ng/mL • PSA =16.3 ng/mL • PSA =1,400 ng/mL • LHRH analogue therapy • LHRH analogue + bicalutamide (MAB) • LHRH analogue + DES Third-line therapy • September 2012 • September 2010 • October 2013 • PSA =77 ng/mL • PSA =46.5 ng/mL • PSA =868 ng/mL • LHRH analogue + bicalutamide (MAB) • LHRH analogue + DES • Pelvic nodes + skeletal metastasis • Zoledronic acid infusion • Zoledronic acid infusion • LHRH analogue + docetaxel • Prednisolone • Zoledronic acid infusion Fourth-line therapy • May 2013 • April 2012 • PSA =81 ng/mL • PSA =273 ng/mL • No visceral metastasis • No visceral metastasis • LHRH analogue + docetaxel • LHRH analogue + docetaxel • Prednisolone • Prednisolone • Zoledronic acid infusion • Zoledronic acid infusion Fifth-line therapy • June 2013 • PSA =628 ng/mL • No visceral metastasis • LHRH analogue + abiraterone • Prednisolone • Zoledronic acid infusion PSA, prostate specific antigen; LHRH, luteinizing hormone-releasing hormone; MAB, maximal androgen blockade; DES, diethylstilboestrol.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.